… survival benefit prompted us to explore the possible risk factors for brain metastasis (BM)
during the course of EGFR-TKIs therapy from EGFR-mutated advanced lung adenocarcinoma …

… developing metachronous BM during the course of EGFR-TKIs treatment were at a
higher … Our findings confirmed that patients developing metachronous BM during EGFR-TKIs …

… EGFR-TKIs achieved similar treatment responses in terms of PFS and OS in the EGFR-mutated
NSCLC patients with brain metastases. … their treatment courses, including 2 patients who …

… brain metastasis. However, these studies are confounded by follow-up time bias. We performed
a competing risk analysis of brain metastasis … of brain metastasis in EGFR+ patients at 3 …

… 25%–40% of NSCLC patients develop brain metastases during their disease course. Citation1,…
analysis demonstrated that EGFR-TKIs are an effective treatment for NSCLC patients with …

… risk factor for poor OS. In conclusion, using EGFR-TKI alone for … EGFR-TKIs and EGFR-TKIs
alone in Cerebral metastatic … progression and subsequent treatment course according to the …

… status are risk factors for developing brain metastases. … effectiveness of EGFR-TKIs in the
treatment of brain metastases, … that asymptomatic disease during the patient’s course was not …

… with BM during treatment with EGFR-TKIs, or insufficient follow-up. Overall survival (OS)
was measured from the date of brain metastases. Independent prognostic factors were …

… growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs… with lung cancer develop BM
during the course of their … investigating the risk factors for BM and the prognostic factors of …

… TKI and EGFR-TKIs + SRS/WBRT are more effective and potentially acceptable for EGFR-mutant
NSCLC with brain metastases … In the current study, treatment-class level analyses were …